Cancer startup could be 8th Boston-area biotech IPO of 2022


A Watertown startup testing a drug licensed from Eli Lilly & Co. in midstage trials has filed for a $100 million IPO.

Previous Southern Research launches bacteria into space to explore cancer treatment
Next Chick-fil-A plans first Northtowns location, national chain's fifth in WNY